MYOV stock forecast
Our latest prediction for Myovant Sciences Ltd's stock price was made on the Sept. 28, 2021 when the stock price was at 22.55$.
In the short term (2weeks), MYOV's stock price should outperform the market by 0.62%. During that period the price should oscillate between -9.97% and +10.51%.
In the medium term (3months), MYOV's stock price should underperform the market by -10.03%. During that period the price should oscillate between -38.39% and +23.85%.Get email alerts
Create a solid portfolio with MYOV
About Myovant Sciences Ltd
Myovant Sciences aspires to redefine care for women and for men through purpose-driven science, empowering medicines, and transformative advocacy. Myovant Sciences has one FDA-approved medicine, ORGOVYX™ (relugolix), for adult patients with advanced prostate cancer. Its lead product candidate, relugolix combination tablet (relugolix 40 mg, estradiol 1.0 mg, and norethindrone acetate 0.5 mg), is under regulatory review in Europe and the U.S. for women with uterine fibroids and is under development for women with endometriosis. Myovant Sciences is also developing MVT-602, an oligopeptide kisspeptin-1 receptor agonist, which has completed a Phase 2a study for female infertility as part of assisted reproduction. Sumitovant Biopharma, Ltd., a wholly owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd., is its majority shareholder.
At the moment the company generates 67M USD in revenues.
On its last earning announcement, the company reported a loss of -3.13$ per share.
The book value per share is 0.88$
Three months stock forecastSept. 28, 2021
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|